# Study To Assess The Safety And Tolerability Of Increasing Single Doses Of ATR-107 (PF-05230900) In Healthy People

> **NCT01162889** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 70 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Placebo SC Injection
- **DRUG:** ATR-107 (PF-05230900) SC Injection
- **DRUG:** ATR-107 (PF-05230900) SC Injection
- **DRUG:** ATR-107 (PF-05230900) SC Injection
- **DRUG:** ATR-107 (PF-05230900) SC Injection
- **DRUG:** ATR-107 (PF-05230900) SC Injection
- **DRUG:** ATR-107 (PF-05230900) IV Infusion
- **DRUG:** ATR-107 (PF-05230900) IV Infusion
- **DRUG:** ATR-107 (PF-05230900) IV Infusion
- **DRUG:** Placebo IV Infusion
- **DRUG:** ATR-107 (PF-05230900) IV Infusion

## Key facts

- **NCT ID:** NCT01162889
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-06
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 70 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2012-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01162889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01162889, "Study To Assess The Safety And Tolerability Of Increasing Single Doses Of ATR-107 (PF-05230900) In Healthy People". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01162889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*